

FORM 7

MONTHLY PROGRESS REPORT

Name of Listed Issuer: Breathtec Biomedical Inc. (the “**Issuer**” or the “**Company**”).

Trading Symbol: BTH

Number of Outstanding Listed Securities: 38,450,198

Date: August 19, 2016

Report on Business

1. Provide a general overview and discussion of the development of the Issuer’s business and operations over the previous month. Where the Issuer was inactive disclose this fact.

During the month of May 2016, the Company commenced trading on the OTCQB® Venture Market in the United States under the symbol “BTHCF” and continued research and development efforts.

2. Provide a general overview and discussion of the activities of management.

During the month of May 2016, Management has been focusing on engaging a product development firm, located in Gainesville Florida, specializing in electronic prototype manufacturing to help the Company advance the development of our FAIMS technology platform.

3. Describe and provide details of any new products or services developed or offered. For resource companies, provide details of new drilling, exploration or production programs and acquisitions of any new properties and attach any mineral or oil and gas or other reports required under Ontario securities law.

None.

4. Describe and provide details of any products or services that were discontinued. For resource companies, provide details of any drilling, exploration or production programs that have been amended or abandoned.

None.

5. Describe any new business relationships entered into between the Issuer, the Issuer’s affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship.

None.

6. Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer's affiliates or third parties or cancellation of any financing arrangements that have been previously announced.

None.

7. Describe any acquisitions by the Issuer or dispositions of the Issuer's assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State how the consideration was determined and whether the acquisition was from or the dispositions was to a Related Person of the Issuer and provide details of the relationship.

None.

8. Describe the acquisition of new customers or loss of customers.

None.

9. Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trade-marks.

None.

10. Report on any employee hirings, terminations or lay-offs with details of anticipated length of lay-offs.

None.

11. Report on any labour disputes and resolutions of those disputes if applicable.

None

12. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.

None.

13. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.

None.

14. Provide details of any securities issued and options or warrants granted.

Security	Number Issued	Details of Issuance	Use of Proceeds
Common shares	1,000,000	Issued 1,000,000 common shares pursuant to the license agreement signed with Technion – Israel Institute of Technology.	N/A
Common shares	15,000	Exercise of 15,000 stock options for proceeds of \$3,750.	General corporate purposes.

15. Provide details of any loans to or by Related Persons.

None.

16. Provide details of any changes in directors, officers or committee members.

None.

17. Discuss any trends which are likely to impact the Issuer including trends in the Issuer's market(s) or political/regulatory trends.

The Issuer's business involves certain risks and uncertainties that are inherent to the Issuer's industry. Please refer to the "Risk Factors" section of the Issuer's Long Form Prospectus filed on January 28, 2016, which is available on SEDAR at www.sedar.com or please refer to the "Risks Related To The Business" section of the Issuer's management discussion and analysis for the nine months ended May 31, 2016, which is available on SEDAR at www.sedar.com.

Certificate Of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
2. As of the date hereof there were is no material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to the Exchange that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all Exchange Requirements (as defined in CNSX Policy 1).
4. All of the information in this Form 7 Monthly Progress Report is true.

Dated August 19, 2016

Michael Sadhra
Name of Director or Senior
Officer

"Michael Sadhra"
Signature

Director/CFO
Official Capacity

Issuer Details Name of Issuer Breathtec Biomedical Inc.	For Month End May 2016	Date of Report YY/MM/D 2016/08/19
Issuer Address Suite 890 – 789 West Pender Street		
City/Province/Postal Code Vancouver, BC V6C 1H2	Issuer Fax No. NA	Issuer Telephone No. (604) 218-6281
Contact Name Michael Sadhra	Contact Position Director/CEO	Contact Telephone No. (604) 218-6281
Contact Email Address info@breathtecbiomedical.com	Web Site Address www.breathtecbiomedical.com	

